Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (341-350 of 361) with videos related to

Pageof 37
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2020
Autoantibody Landscape in Patients with Advanced Prostate CancerWilliam S Chen, Winston A Haynes, Rebecca Waitz, et al.
European Urology|March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 17, 2013
Prostate cancer, version 1.2014James L Mohler, Philip W Kantoff, Andrew J Armstrong, et al.
Prostate Cancer and Prostatic Diseases|February 27, 2019
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancerNicholas G Nickols, Ramin Nazarian, Shuang G Zhao, et al.
Nature Communications|December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancerSoumyajit Roy, Yilun Sun, Maha Hussain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2016
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced NeuropathyDaniel L Hertz, Kouros Owzar, Sherrie Lessans, et al.
Nature Communications|December 22, 2021
The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancerNeha Singh, Varune R Ramnarine, Jin H Song, et al.
The New England Journal of Medicine|December 12, 2012
Abiraterone in metastatic prostate cancer without previous chemotherapyCharles J Ryan, Matthew R Smith, Johann S de Bono, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 7, 2016
Prostate Cancer, Version 1.2016James L Mohler, Andrew J Armstrong, Robert R Bahnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2016
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Howard I Scher, Michael J Morris, Walter M Stadler, et al.
Pageof 37

Showing results (341-350 of 361) with videos related to

Sort By:
Pageof 37
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2020
Autoantibody Landscape in Patients with Advanced Prostate CancerWilliam S Chen, Winston A Haynes, Rebecca Waitz, et al.
European Urology|March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 17, 2013
Prostate cancer, version 1.2014James L Mohler, Philip W Kantoff, Andrew J Armstrong, et al.
Prostate Cancer and Prostatic Diseases|February 27, 2019
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancerNicholas G Nickols, Ramin Nazarian, Shuang G Zhao, et al.
Nature Communications|December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancerSoumyajit Roy, Yilun Sun, Maha Hussain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2016
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced NeuropathyDaniel L Hertz, Kouros Owzar, Sherrie Lessans, et al.
Nature Communications|December 22, 2021
The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancerNeha Singh, Varune R Ramnarine, Jin H Song, et al.
The New England Journal of Medicine|December 12, 2012
Abiraterone in metastatic prostate cancer without previous chemotherapyCharles J Ryan, Matthew R Smith, Johann S de Bono, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 7, 2016
Prostate Cancer, Version 1.2016James L Mohler, Andrew J Armstrong, Robert R Bahnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2016
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Howard I Scher, Michael J Morris, Walter M Stadler, et al.
Pageof 37